Table of Contents

Creating a Success of ePedigree and RFID in Pharma (Strategic Focus) - With the introduction of increasingly more stringent legislation surrounding pharmaceutical supply chain management, RFID and ePedigree are likely to have a significant increase in their take up on a global basis.

Product Code: dmtc2200

Price: $3395

Publication Date: 30-Jun-2008


Overview

Introduction

The pharmaceutical industry is facing increasing pressures to introduce ePedigree and RFID solutions into their supply chains. This will create a number of opportunities for vendors to develop their business in the area, though it will prove very challenging.

Scope

Highlights

RFID has been a hyped solution in the pharmaceutical industry for a number of years. This report assesses the drivers and inhibitors behind ePedigree and RFID and the strategy vendors need to adopt to achieve success.

Reasons to Purchase


Overview

1

Catalyst

1

Summary

1

Key Messages

2

Counterfeiting is an increasing problem for the pharmaceutical industry

2

Legislation could be key to the success of ePedigree and RFID

2

Implementations of ePedigree and RFID will not be simple

2

Geographic differences add an extra layer of complexity

2

Table of Contents

3

Table of figures

4

Market Opportunity

5

RFID can help solve many of pharma's pain points

5

RFID is a solution that is becoming more advanced and cost effective

6

ePedigree is a critical technology for the development of anti-counterfeiting measures in pharma

6

Understanding the difference between ePedigree and serialization

6

Pharma companies often choose 2D barcodes over RFID

7

The need for RFID is being driven from multiple directions but legislation is primary

7

The prevalence of counterfeiting is driving the need for RFID

7

The sale of drugs through the internet has proved a problem for preventing the spread of counterfeit drugs

8

The increase of legislation will help to drive the uptake of RFID

8

Uncertainty around legislation makes the market a challenging environment

8

RFID and ePedigree can help with drug recall

9

2D barcodes do not offer a long term solution

9

There are a number of significant inhibitors holding the RFID market back

10

A number of pharma companies have a lack of confidence in RFID

10

RFID has yet to establish a compelling ROI

10

RFID is too dependent on the legislation that administrators may decide to introduce

10

The structure of the RFID market in pharma

11

Counterfeiting is a growing problem in the developing world

11

The US will be the dominant market, but implementations will often be global

11

Europe is introducing various legislation but some countries are not waiting for the EU

12

Customer Impact:

13

Pharma companies need to prepare for the introduction of a variety of legislation

13

The delay in the Californian legislation means that pharma companies will not miss the deadline

13

Preparation for the future is key

13

Irrespective of legislation, pharma companies should be forward thinking

14

Forward thinking means not shying away from innovative technology

14

Pharma manufacturers must not get caught up in a fight with wholesalers

14

Different types of companies need different policies

15

Not all vendors are suitable for ePedigree and RFID implementations

15

The complex pharma supply chain makes RFID implementations particularly challenging

16

Supply chains differ considerably across the markets

16

The landscape of future implementations is hard to judge

19

Vendors need to think carefully about their five year plan

19

Pharma manufacturers should seek to work with all stakeholders along the supply chain

19

The development of standards will prove crucial for future success

19

Competitive Landscape

21

Accenture

22

Positioning

22

Alien Technology

23

Positioning

23

Blue Vector

24

Positioning

24

Hewlett Packard Company

25

Positioning

25

SAP

26

Positioning

26

What does the future hold?

27

Go to Market

28

Vendors must not fall into the trap of becoming a solution looking for a problem

28

A deep knowledge of life sciences is key to prevent this

28

Vendors need to concentrate on bringing ePedigree and RFID to the wider market

28

An understanding of the different needs in each market is imperative

28

Well developed partnerships are crucial in order for ePedigree to succeed

29

Flexibility also remains important

29

APPENDIX

30

Definitions

30

Methodology

30

Further reading

30

Ask the analyst

31

Datamonitor consulting

31

Disclaimer

31

List of Figures

 

Figure 1: US pharmaceutical supply chain

17

Figure 2: UK pharmaceutical supply chain

18

Figure 3: Accenture SWOT analysis

22

Figure 4: Alien Technology SWOT analysis

23

Figure 5: Blue Vector SWOT analysis

24

Figure 6: Hewlett-Packard SWOT analysis

25

Figure 7: SAP SWOT analysis

26


Contact Datamonitor on:

Datamonitor USADatamonitor EuropeDatamonitor GermanyDatamonitor Asia PacificDatamonitor Japan
245 Fifth AveCharles HouseKastor & PolluxLevel 46Wakamatsu Bldg 7F
4th Floor108-110 Finchley RoadPlatz der Einheit 12 Park Street3-3-6 Nihonbashi-Honcho
New York, NY 10016London NW3 5JJ60327 FrankfurtSydney, NSW 2000Chuo-ku
USAUnited KingdomDeutschlandAustraliaTokyo 103-0023
    Japan
     
t: +1 212 686 7400t: +44 20 7675 7000t: +49 69 9750 3119t: +61 2 8705 6900t: +81 3 6202 7681
f: +1 212 686 2626f: +44 20 7675 7500f: +49 69 9750 3320f: +61 2 8705 6901f: +81 3 4512 8117
e: usinfo@datamonitor.come: eurinfo@datamonitor.come: deinfo@datamonitor.come: apinfo@datamonitor.come: jpinfo@datamonitor.com

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that Datamonitor delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such Datamonitor can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

© Datamonitor 30-Jun-2008

This report is a licensed product and is not to be photocopied

www.datamonitor.com